Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gamma-glutamyltransferase light chain family member 3 (GGTLC3) is a member of the gamma-glutamyltransferase (GGT) family, which includes enzymes responsible for cleaving gamma-glutamyl peptide bonds in glutathione and other peptides[1][4]. Unlike canonical GGT1, GGTLC3 contains a region homologous to the light chain subunit of GGT but lacks the heavy chain necessary for membrane anchoring and typical enzymatic activity[1][4]. As such, GGTLC3 is considered a "light chain-only" member of this family and is of uncertain or *putative* glutathione hydrolase function. While there is evidence for the involvement of canonical GGTs in glutathione metabolism, drug detoxification, and roles in certain diseases, there are currently no validated drug interactions, direct disease associations, or established roles for GGTLC3 in human physiology or as a therapeutic target[4][1][5][6]. GGTLC3 is predicted to have glutathione hydrolase activity and possible involvement in leukotriene metabolism, but this is not experimentally validated[6][4]. The gene is cataloged on chromosome 22, and its dysfunction has been reported in genetic association datasets related to rare diseases such as glutathionuria and some types of cataracts[4]. No specific biomarkers, therapeutic implications, or significant safety concerns have been established for GGTLC3 in clinical or pharmacological contexts[1][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-glutamyltransferase light chain family member 3 (GGTLC3).